Womens Health Investment Outlook 2026

Call to action4 The opportunity facing the sector requires a multistakeholder approach to create conditions for sustained investment and long-term growth in women’s health. Realizing the full potential of women’s health will require targeted, cross-sector leadership. Investors, industry, policy-makers, payers, philanthropies, researchers and others have a critical role to play in closing the women’s health funding gap and scaling innovation. There is a clear need for multistakeholder platforms to encourage this type of collaboration. These platforms could enable partnership opportunities, reduce barriers to investment and spotlight investment areas that require additional support to reach commercial viability. They can also connect siloed efforts across science, policy and investment, ensuring that early discovery, translational research and capital flows are guided by both patient need and commercial feasibility. Below are six imperatives for action that, taken together, can transform women’s health from a fragmented field into a cohesive, scalable and investable market. Build a demand-driven evidence base to de-risk investment and identify scalable opportunities Stakeholders: Researchers, industry, public and private funders of research A robust evidence base is essential to fuel the innovation and investment pipeline. Foundational science clarifies how women’s health conditions develop and identifies where innovation is possible, laying the groundwork for viable, evidence-based investment opportunities. Understanding the biology and pathophysiology of women’s health conditions also strengthens target validation, sharpens product design and increases the likelihood of successful translation. Robust epidemiology and outcomes data helps to quantify disease burden, revealing unmet needs and market potential. Translational and clinical research then help test causal links and validate mechanisms, while implementation and real-world evidence prove whether solutions can perform at scale. Without this continuum of evidence, investors lack the visibility and confidence required to back new entrants and bring effective products to market. Equally important is ensuring that increasingly scarce research dollars are directed towards investable, demand-driven interventions. That means aligning research priorities with both the greatest unmet health needs and the strongest potential markets, indicating where better evidence or new technologies could meaningfully improve outcomes and generate sustainable returns. Target product profiles (TPPs) could serve as a shared tool that defines what “investable innovation” looks like in women’s health, outlining target indications, desired outcomes and value propositions that meet both patient need and market viability. Today, too many insights remain trapped in academia, without the funding or partnerships to move discoveries into drug development, diagnostics or commercial products. Stronger bridges among academia, industry and investors, as well as targeted philanthropic resources and public-sector funding for early-stage discovery, can help move promising science from laboratory to market. Proof point: Establishing the causal link between HPV and cervical cancer transformed a scientific insight into a multibillion-dollar market. The discovery defined clear biological targets, enabling the development of vaccines and diagnostic assays. Global immunization programmes then created predictable, large-scale demand. Today, HPV vaccines are among the most widely adopted immunizations worldwide, and the cervical cancer diagnostics and treatment sector alone exceeds $8 billion, projected to grow by more than 8% annually.108 When foundational research is properly funded and translated, it builds markets and attracts investment.1 Women’s Health Investment Outlook 31